There is a lot of evidence to show that the yeast beta-glucan has immunomodulatory, anti-inflammatory, anti-infective effects.However,few work was done on the relationship between yeast bata-glucan and the immune function of diabetic patients. This is a randomized double-blind trial, aiming to study the effect of yeast beta-glucan on immune system of prediabetic patients. Firstly, the investigators will go into the efficacy of yeast beta-glucan on improving the clinical symptoms of prediabetics. Secondly, the investigators will study the mechanism of yeast beta-glucan on enhancing the immune function and improving the inflammatory response.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
52
Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Huazhong University of Science and Technology
Wuhan, Hubei, China
RECRUITINGChanges in the differentiation rates of some peripheral blood mononuclear cells (PBMCs)
Extract and isolate PBMCs from participants. Using flow cytometry to detect the differentiation rates of some PBMCs（Peripheral Blood Mononuclear Cells）inculding T, B, NK, CD4+, CD8+, CD19+, CD138+, CD3+ and CD45+ cells
Time frame: At 0 week, 6th week, 12th week in the intervention period.
Changes in inflammatory factors
Using ELISA to detect the expression level of TNF-α, IL-6, IL-1β, IL-12, IL-10, TGF-β
Time frame: At 0 week, 6th week, 12th week in the intervention period.
Changes in blood glucose level
FPG(fasten plasma glucose), OGTT（oral glucose tolerance test）
Time frame: At 0 week, 12th week in the intervention period.
Changes in gut microbiota
High-throughput 16S DNA gene amplicon sequencing performed on the Illumina HiSeq platform.
Time frame: At 0 week, 6th week, 12th week in the intervention period.
Changes in RTI(respiratory tract infection)
Observe the clinical symptoms of respiratory infections in two groups of patients
Time frame: Every week across the intervention peroid，an average of 3 months.
Changes in islet function
C-peptide level
Time frame: At 0 week, 12th week in the intervention period.
Changes in SCFA (short chain fatty acids)
Using GC-MS to detect fecal and plasma SCFA
Time frame: At 0 week, 6th week, 12th week in the intervention period.
Changes in blood lipids profile
Fasting plasma Total cholesterol, Low Density Lipoprotein, High Density Lipoprotein and triglycerides.
Time frame: At 0 week, 12th week in the intervention period.
Changes in hepatorenal function
Using automatic biochemical analyzer to detect creatinine, urea nitrogen, alanine aminotransferase, aspartate aminotransferase and so on
Time frame: At 0 week, 12th week in the intervention period.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.